Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27411240 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL18552085 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL12673653 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL24899341 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL2177917 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL24390490 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL27407839 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL27409367 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL27408102 | 0.98 | GLP1R (0.58) | GLP1RNOD1FOLH1GLO1EPHX2 | |
| SCHEMBL23733386 | 0.98 | GLP1R (0.58) | GLP1RNOD1FOLH1GLO1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK A/S (DK) | 2023-10-19 | — | — | US | disclosed |
| EP-4166575-A1 | SEMAGLUTIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Ningbo Kunpeng Biotech Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| WO-2022129526-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022090448-A1 | NOVEL ACYLATING REAGENTS | NOVO NORDISK A/S (DK) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090447-A1 | GLP-1, GIP AND GLUCAGON RECEPTOR TRIPLE AGONISTS | NOVO NORDISK A/S (DK) | 2022-05-05 | — | — | WO | disclosed |
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2020-05-28 | — | — | US | disclosed |
| EP-2513141-B1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331803-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 197/4885FOLH1 1525/4885 |
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | EGFR, VEGFA, ERBB2 | GLP1R 30/4885NOD1 4450/4885FOLH1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.